Literature DB >> 12851873

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

J Tilman Gerlach1, Helmut M Diepolder, Reinhart Zachoval, Norbert H Gruener, Maria-Christina Jung, Axel Ulsenheimer, Winfried W Schraut, C Albrecht Schirren, M Waechtler, M Backmund, Gerd R Pape.   

Abstract

BACKGROUND & AIMS: Acute hepatitis C virus infection accounts for approximately 20% of cases of acute hepatitis today. The aim of this study was to define the natural course of the disease and to contribute to the development of treatment strategies for acute hepatitis C virus.
METHODS: The diagnosis of acute hepatitis C virus in 60 patients was based on seroconversion to anti-hepatitis C virus antibodies or clinical and biochemical criteria and on the presence of hepatitis C virus RNA in the first serum sample.
RESULTS: Fifty-one of 60 (85%) patients presented with symptomatic acute hepatitis C virus. In the natural (untreated) course of acute symptomatic hepatitis C (n = 46), spontaneous clearance was observed in 24 patients (52%), usually within 12 weeks after the onset of symptoms, whereas all asymptomatic patients (n = 9) developed chronic hepatitis C. The start of antiviral therapy (interferon-alpha with or without ribavirin) beyond 3 months after the onset of acute hepatitis induced sustained viral clearance in 80% of treated patients.
CONCLUSIONS: The management of acute hepatitis C has to take into account the high rate of spontaneous viral clearance within 12 weeks after the onset of symptomatic disease. Treatment of only those patients who remain hepatitis C virus RNA positive for more than 3 months after the onset of disease led to an overall viral clearance (self-limited and treatment induced) in 91% of patients, and unnecessary treatment was avoided in those with spontaneous viral clearance. Patients with asymptomatic acute hepatitis C virus infection are unlikely to clear the infection spontaneously and should be treated as early as possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851873     DOI: 10.1016/s0016-5085(03)00668-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  134 in total

1.  The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models.

Authors:  Yongshui Fu; Wenjie Xia; Yizhong Wang; Linwei Tian; Oliver G Pybus; Ling Lu; Kenrad Nelson
Journal:  Transfusion       Date:  2010-04-23       Impact factor: 3.157

2.  Making the best of a bad situation: early chronic nosocomial HCV infection.

Authors:  Carmi Santos; Steven K Herrine
Journal:  Dig Dis Sci       Date:  2010-05-18       Impact factor: 3.199

Review 3.  Treatment of acute HCV infection.

Authors:  Jason Grebely; Gail V Matthews; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-22       Impact factor: 46.802

Review 4.  Current therapy for hepatitis C.

Authors:  Mireen Friedrich-Rust; Stefan Zeuzem; Christoph Sarrazin
Journal:  Int J Colorectal Dis       Date:  2005-09-21       Impact factor: 2.571

Review 5.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

6.  Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France.

Authors:  C Brouard; P Pradat; E Delarocque-Astagneau; C Silvain
Journal:  Epidemiol Infect       Date:  2007-08-16       Impact factor: 2.451

7.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

8.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

9.  Pegylated interferon and ribavirin treatment for hepatitis C virus infection.

Authors:  Emilio Palumbo
Journal:  Ther Adv Chronic Dis       Date:  2011-01       Impact factor: 5.091

10.  Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.

Authors:  Deirdre Sawinski; Kimberly A Forde; Vincent Lo Re; David S Goldberg; Jordana B Cohen; Jayme E Locke; Roy D Bloom; Colleen Brensinger; Joe Weldon; Justine Shults; Peter P Reese
Journal:  Am J Kidney Dis       Date:  2019-01-29       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.